<VariationArchive RecordType="classified" VariationID="1070140" VariationName="NC_000014.8:g.(?_88391504)_88423173del" VariationType="Deletion" Accession="VCV001070140" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-15" DateCreated="2021-12-02" MostRecentSubmission="2021-12-02">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1057660" VariationID="1070140">
      <GeneList>
        <Gene Symbol="GALC" FullName="galactosylceramidase" GeneID="2581" HGNC_ID="HGNC:4115" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>14q31.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="87933014" stop="87993667" display_start="87933014" display_stop="87993667" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="88399357" stop="88460008" display_start="88399357" display_stop="88460008" Strand="-" />
          </Location>
          <OMIM>606890</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000014.8:g.(?_88391504)_88423173del</Name>
      <VariantType>Deletion</VariantType>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.8" sequenceAccession="NC_000014" sequenceVersion="8" change="g.(?_88391504_88423173del" Assembly="GRCh37">
            <Expression>NC_000014.8:g.(?_88391504_88423173del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.8" sequenceAccession="NC_000014" sequenceVersion="8" change="g.(?_88391504)_88423173del" Assembly="GRCh37">
            <Expression>NC_000014.8:g.(?_88391504)_88423173del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000014.8:g.(?_88391504)_88423173del AND Galactosylceramide beta-galactosidase deficiency" Accession="RCV001382170" Version="2">
        <ClassifiedConditionList TraitSetID="1051">
          <ClassifiedCondition DB="MedGen" ID="C0023521">Galactosylceramide beta-galactosidase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-03-29" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-03-29" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-12-02" MostRecentSubmission="2021-12-02">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">22073273</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26795590</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7581365</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1051" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2446" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Krabbe leukodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Globoid cell leukoencephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Galactosylceramide beta-galactosidase deficiency</ElementValue>
                <XRef ID="Krabbe+leukodystrophy/4044" DB="Genetic Alliance" />
                <XRef ID="192782005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leukodystrophy, Globoid Cell</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GCL</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">GLD</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course.</Attribute>
                <XRef ID="NBK1238" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6844" />
                <XRef ID="6844" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301416</ID>
                <ID Source="BookShelf">NBK1238</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AAP, 2021">
                <URL>https://publications.aap.org/pediatrics/article/148/3/e2021053126/181065/Leukodystrophies-in-Children-Diagnosis-Care-and</URL>
                <CitationText>Leukodystrophies in Children: Diagnosis, Care, and Treatment, Pediatrics (2021) 148 (3): e2021053126.</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Infantile.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, elevated psychosine, Krabbe Disease (infantile form), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Krabbe disease: galactocerebrosidase deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Later-Onset.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, mildly elevated psychosine, Krabbe Disease (late-onset form), 2022</CitationText>
              </Citation>
              <XRef ID="487" DB="Orphanet" />
              <XRef ID="C0023521" DB="MedGen" />
              <XRef ID="MONDO:0009499" DB="MONDO" />
              <XRef Type="MIM" ID="245200" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3106415" SubmissionDate="2021-11-23" DateLastUpdated="2021-12-02" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_000153.3_14_Deletion (exons 11-17)_88391503_88423173|MedGen:C0023521" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001580802" DateUpdated="2021-12-02" DateCreated="2021-05-10" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-03-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">7581365</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22073273</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26795590</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22073273</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exons 11-17 of the GALC gene. While it is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. Loss-of-function variants in GALC are known to be pathogenic. This particular variant is consistent with the well known 30kb deletion, which is the most common cause of Krabbe disease in the European population, found in more than 30% of affected individuals investigated and at a frequency of 0.2% in a sample of 2,330 control European individuals (PMID: 7581365, 22073273, 26795590). This variant has been associated with an increased risk for primary open-angle glaucoma, but the clinical relevance of this finding is unclear (PMID: 22073273). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALC" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000014.8:g.(?_88391504)_88423173del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023521" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10689444</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3106415" TraitType="Disease" MappingType="XRef" MappingValue="C0023521" MappingRef="MedGen">
        <MedGen CUI="C0023521" Name="Galactosylceramide beta-galactosidase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

